anti-CD5 CAR T-cell therapy (Curocell)

N/A

Report date: 2025/06/11 10:25:59

Base Information

Drug Nameanti-CD5 CAR T-cell therapy (Curocell)
Drug Alias Nameanti-CD5 CAR gamma delta T-cell therapy (Curocell)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT-cell surface glycoprotein CD5 modulatorsT lymphocytes stimulants
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCurocell Inc
China Registration ClassN/A

Develop Information

Active CompaniesCurocell Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A